Amex resources is a small explorer on track for iron sands mine in Fiji. A robust feasibility study supports a 20-year mine life with low operating costs.
Fleetwood is feeling the effects of reduced occupancy in one of its villages and RBS has become more cautious on the near-term, but not longer term, outlook.
FlexiGroup has grabbed more broker attention with a robust outlook and high potential, despite the much-publicised difficulties in the retail and finance sectors.
A farm-in deal with Santos sees DJ Carmichael reiterate a positive view on Central Petroleum.
Share price gains over the past year prompted RBS Australia to downgrade to a Hold rating last month, but Moelis continues to rate junior telco BigAir as a Buy given a solid growth outlook.
Elk Petroleum offers an attractive production growth profile from Enhanced Oil Recovery operations in the US and DJ Carmichael initiates coverage with a Buy rating.
Bionomics has moved into the cancer stem cell field through a US acquisition and on the news Bell Potter reiterates its Buy rating for the stock.
Despite a drug crystallisation issue pushing back its testing timeline, Phosphagenics continues to offer upside through its drug patch delivery technology in the view of Bell Potter.
Bell Potter quite likes Neuren Pharmaceuticals because of progress with drugs for Traumatic Brain Injury and Autism Spectrum Disorders, plus developments in a Parkinson’s Disease compound offer.
Macquarie has initiated coverage on junior telco Amcom with an Outperform rating, attracted to expected double-digit earnings growth as the group’s cloud and fibre services expand.